- Opinion
- [Column] Regulations hindering healthcare IT development
- by Jung, Hye-Jin Feb 24, 2020 06:27am
- People say ‘data is petroleum of the future.’ ‘Big Data’ is the key resource and product of data economics and digital economics, but also is a key factor deciding the state competitiveness. With the recently passed Three Data Bills, anonymous information system has been adopted and obfuscated data incorporation between companies or
- Opinion
- [Reporter’s view] MFDS’ eyebrow-raising review dependency
- by Lee, Tak-Sun Feb 24, 2020 06:24am
- Obviously not true, but a series of recent incidents have gotten the public skeptical about Korea’s Ministry of Food and Drug Safety’s (MFDS) independent pharmaceutical review capacity. Many of recent safety issues have surfaced from overseas, and none of them were first found in Korea. Merely in a day, the ministry decided to copy the
- Opinion
- [FOCUS] Distrust caused by pharmaceutical and bio companies
- by Chon, Seung-Hyun Feb 20, 2020 06:34am
- Financial authorities again cut the disclosure of pharmaceutical and bio companies. The Korea Exchange prepared the 'Inclusive Disclosure Guidelines for Pharmaceuticals and Bio-Industry' and recommended that specific disclosure cases be followed and followed in accordance with industry characteristics. The intention is to encourage investors
- Opinion
- [Column] Pharmacist's role during COVID-19 outbreak
- by Jung, Heung-Jun Feb 17, 2020 06:26am
- “Do you have hand sanitizer?” “Do you have masks?” These were the most frequently asked questions at my pharmacy starting from Lunar New Year holiday season when the first case of COVID-19 in Korea was confirmed. It is disheartening to see people looking for hand sanitizer in every pharmacy as if not owning one would kill them.
- Opinion
- [FOUCS] Fundamental issues with listed drug reevaluation
- by Kim, Jung-Ju Feb 13, 2020 06:27am
- The government is currently fine-tuning the detailed draft of Pharmaceutical Reevaluation Standard and Method. Although the initial drafting schedule disclosed at last year’s meeting with pharmaceutical industry and public hearing has been delayed, the government’s commitment on the task is still strong regardless of the urgent issues
- Opinion
- [Reporter’s view]2019n-CoV & safety ignorance of companies
- by Kim, Jin-Gu Feb 12, 2020 06:27am
- Rumor has it that the new coronavirus confirmers 17 and 19 are employees of pharmaceutical companies. The fact is not known. However, it is speculated that they were attending a plastic surgery conference held in Singapore recently, and the KCDC confirmed that they are not doctors. More important than rumor is the possibility that pharm
- Opinion
- All the access in China must be cut off
- by Nho, Byung Chul Feb 11, 2020 06:30am
- 2019n-CoV is a RNA virus belonging to beta corona, similar to SARS or MERS, and is a common infectious disease with high mortality due to the absence of vaccines and treatments. The mortality rate of SARS and MERS was 10% and 30%, respectively. This is due to the level of medical care, and because it has very high gene homology with SARS and
- Opinion
- [Reporter’s View]Trust is essential to prevent a MERS II
- by Lee, Hye-Kyung Feb 5, 2020 02:22am
- As the fourth confirmed person in China's Wuhan Pneumonia (2019-nCoV Infection) emerges, there is growing concern over whether outbreak of the Middle East Respiratory Syndrome (MERS) that occurred in 2015 could be reproduced. Beyond the concerns, people who have experienced the MERS crisis, as well as nursing institutions such as hospitals, c
- Opinion
- [Reporter’s view]Dilemma of salesperson suicide & reporting
- by Eo, Yun-Ho Feb 3, 2020 06:23am
- Sad things happen constantly. In the past year, four salespeople who worked for a multinational pharmaceutical company took their own lives. This is the minimum number known and confirmed. The circumstances of the company and the extreme choices are different. However, the common point was that the reason for suicide was 'the company they
- Opinion
- [FOCUS] 10 ‘global new drugs’ promised 10 years ago
- by Chon, Seung-Hyun Jan 15, 2020 06:28am
- In 2011, the government formed Korea Drug Development Fund (KDDF) to provide inter-ministerial level support for developing new drug. Ministry of Science and ICT (MSIT), Ministry of Trade, Industry and Energy (MOTIE) and Ministry of Health and Welfare (MOHW) laid down a plan to develop more than ten global-level new drugs by investing on R&D
